• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Retroviral replicating vector-mediated gene therapy for lung cancer

Research Project

Project/Area Number 18K08773
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55040:Respiratory surgery-related
Research InstitutionHokkaido University

Principal Investigator

Hiraoka Kei  北海道大学, 医学研究院, 客員研究員 (10719587)

Co-Investigator(Kenkyū-buntansha) 高橋 雅道  国立研究開発法人国立がん研究センター, 中央病院, 医長 (10436454)
平野 聡  北海道大学, 医学研究院, 教授 (50322813)
土川 貴裕  北海道大学, 大学病院, 講師 (50507572)
七戸 俊明  北海道大学, 医学研究院, 准教授 (70374353)
中村 透  北海道大学, 医学研究院, 助教 (70645796)
加賀 基知三  北海道大学, 大学病院, 講師 (80224335)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsレトロウイルス / プロドラッグ / 肺癌 / 遺伝子治療 / ウイルスベクター
Outline of Final Research Achievements

In this study, the application of prodrug-activator gene therapy mediated by a retroviral replicating vector (RRV) was attempted as a new therapeutic approach for lung cancer. With this system, a prodrug (antifungal drug) administered into the body is converted into an anticancer drug inside the cancer cells infected with a viral vector and transduced with a therapeutic gene, and selectively destroys only the cancer cells. As a result of this study, it was confirmed that this newly developed viral vector can transduce therapeutic genes into cancer cells efficiently in both cultured human lung cancer cells and orthotopic animal experimental models, and systemic administration of a prodrug showed a strong cell-killing effect and resulted in significant inhibition of tumor growth. In terms of safety, there was no evidence of uncontrollable spread of RRV to adjacent normal organs or tissues.

Academic Significance and Societal Importance of the Research Achievements

本研究によって肺癌における増殖型レトロウイルスを用いたプロドラッグ治療システムが確立されれば、他のプロドラッグを本治療システムに応用した新規治療の開発が期待できるだけでなく、予後不良な他の難治性癌に対しても応用可能であり、本研究から期待される成果の適応範囲は極めて広範囲である。また、本研究で得られる有効性・安全性データは、肺癌に対する臨床試験へ向けた前臨床研究へと展開が可能であり、北海道大学や北海道臨床開発機構を始めとする関連機関との連携を図りながら環境整備を進めることで、国内臨床試験の速やかな導入が期待できる。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2020 2019

All Presentation (4 results) (of which Int'l Joint Research: 1 results)

  • [Presentation] Therapeutic activity of prodrug activator gene therapy with Toca 511 in experimental models of lung cancer2020

    • Author(s)
      櫛谷洋樹、平岡 圭、鈴木友啓、猪子和穂、稲垣亮仁、丹羽弘貴、佐々木勝則、中村 透、土川貴裕、七戸俊明、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] Retroviral replicating-vector mediated gene therapy activates anti-tumor immune responses in an immunocompetent pancreatic cancer model2020

    • Author(s)
      丹羽弘貴、中村 透、櫛谷洋樹、猪子和穂、平岡 圭、稲垣亮仁、土川貴裕、七戸俊明、Douglas J. Jolly、Noriyuki Kasahara、平野 聡
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 膵癌に対するプロドラッグ活性化遺伝子治療(Toca 511/5-FC治療)で誘導された抗腫瘍免疫応答による腫瘍縮小効果2020

    • Author(s)
      丹羽弘貴、中村 透、櫛谷洋樹、猪子和穂、土川貴裕、平岡 圭、七戸俊明、平野 聡
    • Organizer
      第100回北海道医学大会腫瘍系分科会・第122回北海道癌談話会
    • Related Report
      2020 Annual Research Report
  • [Presentation] Therapeutic Activity of Gene Therapy with Toca 511 & Toca FC for Esophageal Cancer2019

    • Author(s)
      Tomohiro Suzuki
    • Organizer
      ASGCT 22nd Annual Meeting
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi